Scientific & Regulatory Consulting•Toxicology & Product Safety
Request basket0
PDE / ADE · OEL / OEB

Home→PDE/ADE · OEL/OEB Profiles → Baxdrostat→

Baxdrostat PDE report and OEL report profile

Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.

CAS Registry Number
1428652-17-8
Molecular formula
C22H25N3O2
Molecular weight
363.46 g/mol
Drug class
Selective aldosterone synthase inhibitor (CYP11B2 inhibitor)antihypertensive
Mechanism of action
Inhibits human aldosterone synthase, reducing aldosterone production and plasma aldosterone concentrations. This reduces renal sodium and water retention and lowers blood pressure; baxdrostat is more potent and selective for aldosterone synthase than the related cortisol-synthesis enzyme 11β-hydroxylase.
Indications / reported uses
  • Treatment of hypertension in adults who are not adequately controlled on other agents, in combination with other antihypertensive drugs, under the US FDA BAXFENDY indication (initial US approval 2026)

Sources: US FDA prescribing information — BAXFENDY (revised May 2026) · FDA product information

View request basketPrefer email? [email protected]
PDE / ADE derivationOEL derivationOEB / OHC bandingRequest basket0
Substance information

Drug class, mechanism of action and general use cases

Drug class

Selective aldosterone synthase inhibitor (CYP11B2 inhibitor); antihypertensive

Mechanism of action

Inhibits human aldosterone synthase, reducing aldosterone production and plasma aldosterone concentrations. This reduces renal sodium and water retention and lowers blood pressure; baxdrostat is more potent and selective for aldosterone synthase than the related cortisol-synthesis enzyme 11β-hydroxylase.

General use cases

  • Treatment of hypertension in adults who are not adequately controlled on other agents, in combination with other antihypertensive drugs, under the US FDA BAXFENDY indication (initial US approval 2026)

For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.

Assessment scope

Project-specific PDE/ADE and OEL/OEB support

Scope is agreed for the exact substance form, intended use, exposure route, workplace context and available toxicological evidence.

  • PDE/ADE: critical effects, point of departure and justified adjustment factors.
  • OEL: inhalation hazards, exposure duration and workplace conditions.
  • OEB/OHC: evidence-based banding where requested; a band is not a numerical OEL.
  • Report: scientific rationale, source data, assumptions, uncertainties and limitations.
Assessment scope

PDE/ADE and OEL/OEB assessment

ReguSight provides project-specific support for Baxdrostat PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Baxdrostat Permitted Daily Exposure (PDE) report (the Baxdrostat PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Baxdrostat Occupational Exposure Limit (OEL) report (the Baxdrostat OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.

Assessment may cover

  • PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
  • OEL derivation considering relevant hazards, exposure route, duration and workplace conditions.
  • OEB/OHC banding where requested and supported by the evidence; an exposure band is not a numerical OEL.
  • Review of substance identity, evidence quality, uncertainty and data gaps.
PDE/ADE, OEL & OEB/OHC regulatory framework

The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.